Last reviewed 2026-04-23 · How we verify

cefazolin, erythromycin, clarithromycin

Samsung Medical Center · Phase 3 active Small molecule

cefazolin, erythromycin, clarithromycin is a Antibiotic combination (cephalosporin + macrolides) Small molecule drug developed by Samsung Medical Center. It is currently in Phase 3 development for Bacterial infections (specific indication unclear from available information).

This is a combination of three antibiotics that work through different mechanisms to inhibit bacterial protein synthesis and cell wall formation.

This is a combination of three antibiotics that work through different mechanisms to inhibit bacterial protein synthesis and cell wall formation. Used for Bacterial infections (specific indication unclear from available information).

Likelihood of approval

60.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	cefazolin, erythromycin, clarithromycin
Sponsor	Samsung Medical Center
Drug class	Antibiotic combination (cephalosporin + macrolides)
Target	Bacterial cell wall (cefazolin); bacterial 50S ribosome (erythromycin, clarithromycin)
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 3

Mechanism of action

Cefazolin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Erythromycin and clarithromycin are macrolide antibiotics that inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides broad-spectrum coverage against gram-positive and some gram-negative bacteria.

Approved indications

Bacterial infections (specific indication unclear from available information)

Common side effects

Gastrointestinal disturbance
Hypersensitivity reaction
Nausea
Diarrhea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

cefazolin, erythromycin, clarithromycin CI brief — competitive landscape report
cefazolin, erythromycin, clarithromycin updates RSS · CI watch RSS
Samsung Medical Center portfolio CI

Frequently asked questions about cefazolin, erythromycin, clarithromycin

What is cefazolin, erythromycin, clarithromycin?

cefazolin, erythromycin, clarithromycin is a Antibiotic combination (cephalosporin + macrolides) drug developed by Samsung Medical Center, indicated for Bacterial infections (specific indication unclear from available information).

How does cefazolin, erythromycin, clarithromycin work?

This is a combination of three antibiotics that work through different mechanisms to inhibit bacterial protein synthesis and cell wall formation.

What is cefazolin, erythromycin, clarithromycin used for?

cefazolin, erythromycin, clarithromycin is indicated for Bacterial infections (specific indication unclear from available information).

Who makes cefazolin, erythromycin, clarithromycin?

cefazolin, erythromycin, clarithromycin is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

What drug class is cefazolin, erythromycin, clarithromycin in?

cefazolin, erythromycin, clarithromycin belongs to the Antibiotic combination (cephalosporin + macrolides) class. See all Antibiotic combination (cephalosporin + macrolides) drugs at /class/antibiotic-combination-cephalosporin-macrolides.

What development phase is cefazolin, erythromycin, clarithromycin in?

cefazolin, erythromycin, clarithromycin is in Phase 3.

What are the side effects of cefazolin, erythromycin, clarithromycin?

Common side effects of cefazolin, erythromycin, clarithromycin include Gastrointestinal disturbance, Hypersensitivity reaction, Nausea, Diarrhea.

What does cefazolin, erythromycin, clarithromycin target?

cefazolin, erythromycin, clarithromycin targets Bacterial cell wall (cefazolin); bacterial 50S ribosome (erythromycin, clarithromycin) and is a Antibiotic combination (cephalosporin + macrolides).

Drug class: All Antibiotic combination (cephalosporin + macrolides) drugs
Target: All drugs targeting Bacterial cell wall (cefazolin); bacterial 50S ribosome (erythromycin, clarithromycin)
Manufacturer: Samsung Medical Center — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Bacterial infections (specific indication unclear from available information)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing